134 related articles for article (PubMed ID: 32273585)
1. CCR5 inhibitor as novel acute graft versus host disease prophylaxis in children and young adults undergoing allogeneic stem cell transplant: results of the phase II study.
Khandelwal P; Fukuda T; Teusink-Cross A; Kashuba ADM; Lane A; Mehta PA; Marsh RA; Jordan MB; Grimley MS; Myers KC; Nelson AS; El-Bietar J; Chandra S; Bleesing JJ; Krupski MC; Davies SM
Bone Marrow Transplant; 2020 Aug; 55(8):1552-1559. PubMed ID: 32273585
[TBL] [Abstract][Full Text] [Related]
2. A Pharmacokinetic and Pharmacodynamic Study of Maraviroc as Acute Graft-versus-Host Disease Prophylaxis in Pediatric Allogeneic Stem Cell Transplant Recipients with Nonmalignant Diagnoses.
Khandelwal P; Fukuda T; Mizuno K; Teusink-Cross A; Mehta PA; Marsh RA; Kashuba ADM; Vinks AA; Davies SM
Biol Blood Marrow Transplant; 2016 Oct; 22(10):1829-1835. PubMed ID: 27498124
[TBL] [Abstract][Full Text] [Related]
3. Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial.
Sandmaier BM; Kornblit B; Storer BE; Olesen G; Maris MB; Langston AA; Gutman JA; Petersen SL; Chauncey TR; Bethge WA; Pulsipher MA; Woolfrey AE; Mielcarek M; Martin PJ; Appelbaum FR; Flowers MED; Maloney DG; Storb R
Lancet Haematol; 2019 Aug; 6(8):e409-e418. PubMed ID: 31248843
[TBL] [Abstract][Full Text] [Related]
4. Extended CCR5 Blockade for Graft-versus-Host Disease Prophylaxis Improves Outcomes of Reduced-Intensity Unrelated Donor Hematopoietic Cell Transplantation: A Phase II Clinical Trial.
Reshef R; Ganetsky A; Acosta EP; Blauser R; Crisalli L; McGraw J; Frey NV; Hexner EO; Hoxie JA; Loren AW; Luger SM; Mangan J; Stadtmauer EA; Mick R; Vonderheide RH; Porter DL
Biol Blood Marrow Transplant; 2019 Mar; 25(3):515-521. PubMed ID: 30315941
[TBL] [Abstract][Full Text] [Related]
5. Clinical and immunologic impact of CCR5 blockade in graft-versus-host disease prophylaxis.
Moy RH; Huffman AP; Richman LP; Crisalli L; Wang XK; Hoxie JA; Mick R; Emerson SG; Zhang Y; Vonderheide RH; Porter DL; Reshef R
Blood; 2017 Feb; 129(7):906-916. PubMed ID: 28057639
[TBL] [Abstract][Full Text] [Related]
6. Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease.
Reshef R; Luger SM; Hexner EO; Loren AW; Frey NV; Nasta SD; Goldstein SC; Stadtmauer EA; Smith J; Bailey S; Mick R; Heitjan DF; Emerson SG; Hoxie JA; Vonderheide RH; Porter DL
N Engl J Med; 2012 Jul; 367(2):135-45. PubMed ID: 22784116
[TBL] [Abstract][Full Text] [Related]
7. Mycophenolate mofetil administered every 8 hours in combination with tacrolimus is efficacious in the prophylaxis of acute graft versus host disease in childhood, adolescent, and young adult allogeneic stem cell transplantation recipients.
Militano O; Ozkaynak MF; Mehta B; van deVen C; Hamby C; Cairo MS
Pediatr Blood Cancer; 2018 Aug; 65(8):e27091. PubMed ID: 29667720
[TBL] [Abstract][Full Text] [Related]
8. Prophylaxis and treatment with mycophenolate mofetil in children with graft-versus-host disease undergoing allogeneic hematopoietic stem cell transplantation: a nationwide survey in Japan.
Kawashima N; Iida M; Suzuki R; Fukuda T; Atsuta Y; Hashii Y; Inoue M; Kobayashi M; Yabe H; Okada K; Adachi S; Yuza Y; Kawa K; Kato K
Int J Hematol; 2019 Apr; 109(4):491-498. PubMed ID: 30694451
[TBL] [Abstract][Full Text] [Related]
9. Comparative Analysis of Calcineurin Inhibitor-Based Methotrexate and Mycophenolate Mofetil-Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation.
Chhabra S; Liu Y; Hemmer MT; Costa L; Pidala JA; Couriel DR; Alousi AM; Majhail NS; Stuart RK; Kim D; Ringden O; Urbano-Ispizua A; Saad A; Savani BN; Cooper B; Marks DI; Socie G; Schouten HC; Schoemans H; Abdel-Azim H; Yared J; Cahn JY; Wagner J; Antin JH; Verdonck LF; Lehmann L; Aljurf MD; MacMillan ML; Litzow MR; Solh MM; Qayed M; Hematti P; Kamble RT; Vij R; Hayashi RJ; Gale RP; Martino R; Seo S; Hashmi SK; Nishihori T; Teshima T; Gergis U; Inamoto Y; Spellman SR; Arora M; Hamilton BK
Biol Blood Marrow Transplant; 2019 Jan; 25(1):73-85. PubMed ID: 30153491
[TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamic Monitoring Predicts Outcomes of CCR5 Blockade as Graft-versus-Host Disease Prophylaxis.
Huffman AP; Richman LP; Crisalli L; Ganetsky A; Porter DL; Vonderheide RH; Reshef R
Biol Blood Marrow Transplant; 2018 Mar; 24(3):594-599. PubMed ID: 29061535
[TBL] [Abstract][Full Text] [Related]
11. Enteric-coated mycophenolate sodium containing GvHD prophylaxis reduces GvHD rate after allogeneic HSCT.
Weber T; Niestadtkötter J; Wienke A; Müller-Tidow C; Müller LP
Eur J Haematol; 2016 Sep; 97(3):232-8. PubMed ID: 26613546
[TBL] [Abstract][Full Text] [Related]
12. Human herpesvirus 6 encephalitis in patients administered mycophenolate mofetil as prophylaxis for graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
Inui Y; Yakushijin K; Okamura A; Tanaka Y; Shinzato I; Nomura T; Ichikawa H; Mizutani Y; Kitao A; Kurata K; Kakiuchi S; Miyata Y; Sanada Y; Kitagawa K; Uryu K; Kawamoto S; Yamamoto K; Matsuoka H; Murayama T; Ito M; Minami H
Transpl Infect Dis; 2019 Feb; 21(1):e13024. PubMed ID: 30414316
[TBL] [Abstract][Full Text] [Related]
13. Use of mycophenolate mofetil and a calcineurin inhibitor in allogeneic hematopoietic stem-cell transplantation from HLA-matched siblings or unrelated volunteer donors: Japanese multicenter phase II trials.
Nakane T; Nakamae H; Yamaguchi T; Kurosawa S; Okamura A; Hidaka M; Fuji S; Kohno A; Saito T; Aoyama Y; Hatanaka K; Katayama Y; Yakushijin K; Matsui T; Yamamori M; Takami A; Hino M; Fukuda T
Int J Hematol; 2017 Apr; 105(4):485-496. PubMed ID: 27943166
[TBL] [Abstract][Full Text] [Related]
14. Cannabidiol for the Prevention of Graft-versus-Host-Disease after Allogeneic Hematopoietic Cell Transplantation: Results of a Phase II Study.
Yeshurun M; Shpilberg O; Herscovici C; Shargian L; Dreyer J; Peck A; Israeli M; Levy-Assaraf M; Gruenewald T; Mechoulam R; Raanani P; Ram R
Biol Blood Marrow Transplant; 2015 Oct; 21(10):1770-5. PubMed ID: 26033282
[TBL] [Abstract][Full Text] [Related]
15. A pilot study of tacrolimus and mycophenolate mofetil graft-versus-host disease prophylaxis in childhood and adolescent allogeneic stem cell transplant recipients.
Osunkwo I; Bessmertny O; Harrison L; Cheung YK; Van de Ven C; del Toro G; Garvin J; George D; Bradley MB; Wolownik K; Wischhover C; Levy J; Skerrett D; Cairo MS
Biol Blood Marrow Transplant; 2004 Apr; 10(4):246-58. PubMed ID: 15077223
[TBL] [Abstract][Full Text] [Related]
16. Post-Transplant Cyclophosphamide and Tacrolimus-Mycophenolate Mofetil Combination Prevents Graft-versus-Host Disease in Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from HLA-Matched Donors.
Carnevale-Schianca F; Caravelli D; Gallo S; Coha V; D'Ambrosio L; Vassallo E; Fizzotti M; Nesi F; Gioeni L; Berger M; Polo A; Gammaitoni L; Becco P; Giraudo L; Mangioni M; Sangiolo D; Grignani G; Rota-Scalabrini D; Sottile A; Fagioli F; Aglietta M
Biol Blood Marrow Transplant; 2017 Mar; 23(3):459-466. PubMed ID: 28039079
[TBL] [Abstract][Full Text] [Related]
17. Severity of acute gastrointestinal graft-vs-host disease is associated with incidence of bloodstream infection after adult allogeneic hematopoietic stem cell transplantation.
Modi A; Rybicki L; Majhail NS; Mossad SB
Transpl Infect Dis; 2020 Feb; 22(1):e13217. PubMed ID: 31769584
[TBL] [Abstract][Full Text] [Related]
18. Graft-versus-host disease prophylaxis with tacrolimus and mycophenolate mofetil in HLA-matched nonmyeloablative transplant recipients is associated with very low incidence of GVHD and nonrelapse mortality.
Sabry W; Le Blanc R; Labbé AC; Sauvageau G; Couban S; Kiss T; Busque L; Cohen S; Lachance S; Roy DC; Roy J
Biol Blood Marrow Transplant; 2009 Aug; 15(8):919-29. PubMed ID: 19589481
[TBL] [Abstract][Full Text] [Related]
19. A phase I/II study of mycophenolate mofetil in combination with cyclosporine for prophylaxis of acute graft-versus-host disease after myeloablative conditioning and allogeneic hematopoietic cell transplantation.
Nash RA; Johnston L; Parker P; McCune JS; Storer B; Slattery JT; Furlong T; Anasetti C; Appelbaum FR; Lloid ME; Deeg HJ; Kiem HP; Martin PJ; Schubert MM; Witherspoon RP; Forman SJ; Blume KG; Storb R
Biol Blood Marrow Transplant; 2005 Jul; 11(7):495-505. PubMed ID: 15983549
[TBL] [Abstract][Full Text] [Related]
20. [Combination of mycophenolate mofetil with cyclosporine A and methotrexate for the prophylaxes of acute graft versus host disease in allogeneic peripheral stem cell transplantation].
Wang J; Song X; Zhang W; Tong S; Hou J; Chen L; Lou J; Li H; Ding X; Min B
Zhonghua Yi Xue Za Zhi; 2002 Apr; 82(8):507-10. PubMed ID: 12133492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]